Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Clene ( (CLNN) ).
Clene, a company involved in developing treatments for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has outlined a potential path for accelerated approval of its CNM-Au8 treatment in ALS through additional biomarker data submission. This development could significantly impact Clene’s operations by potentially speeding up the approval process, enhancing its market position in the neurodegenerative treatment industry, and providing a promising option for stakeholders invested in ALS treatments.
More about Clene
YTD Price Performance: -19.93%
Average Trading Volume: 78,263
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $37.9M
For detailed information about CLNN stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- HRIF, HUV: 2 Canadian ETFs to Boost Your Portfolio Returns
- Alphabet’s Google Asks FTC to Break Microsoft-OpenAI Exclusive Deal
- Amazon Autos Starts Offering Hyundai Cars for Sale to Customers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
